Serum seeks regulatory nod for Ph-III trials of Novavax's Covid vaccine
Serum seeks regulatory nod for Ph-III trials of Novavax’s Covid vaccine
Novavax’s development is two months behind that of AstraZenca. Serum Institute of India (SII) may soon start Phase-III trials of another Covid-19 vaccine being developed by US-based biotechnology company Novavax. SII is seeking regulatory nod from the Indian government to start the trials for this vaccine. Company sources said it can start the trials by January 2021 once the regulatory approval…
View On WordPress












